Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

The treatment of metastatic non –small-cell lung cancer (mNSCLC) patients with EGFR/HER2 exon 20 insertion mutation (i-mut) remains an unmet clinical need. Poziotinib, a new generation tyrosine kinase inhibitor, is currently under investigation as a potential targeted therapy. This compassionate study of its use aims to describe the activity/toxicity of poziotinib in mNSCLC with EGFR/HER2-exon-20-i-mut.

Source: European Journal of Cancer - April 2, 2021 Category: Cancer & Oncology Authors: Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice L Tags: Original Research Source Type: research